Sandu Pharmaceuticals Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sandu Pharmaceuticals Ltd is ₹ 42.11 as of 05 May 15:30 . The P/E Ratio of Sandu Pharmaceuticals Ltd changed from 33.3 on March 2023 to 0 on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 2 years The Market Cap of Sandu Pharmaceuticals Ltd changed from ₹ 50.43 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 2 years The revenue of Sandu Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 178.34 crore as compare to the Sep '25 revenue of ₹ 167.17 crore. This represent the growth of 6.68% The ebitda of Sandu Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 57.79 crore as compare to the Sep '25 ebitda of ₹ 54.92 crore. This represent the growth of 5.23% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 33.58 crore over 7 quarters. This represents a CAGR of 90.11% The Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 49.86 % on March 2025 . This represents a CAGR of 6.54% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd (SPL) was established in 1985.
The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.
Thereafter, it commenced production of manufacturing Unit II in Goa from May, 2002.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of Sandu Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Sandu Pharmaceuticals Ltd or Senores Pharmaceuticals Ltd?

Market cap of Sandu Pharmaceuticals Ltd is 41 Cr while Market cap of Senores Pharmaceuticals Ltd is 4,110 Cr

What are the key factors driving the stock performance of Sandu Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Sandu Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sandu Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd?

As of May 5, 2026, the Sandu Pharmaceuticals Ltd stock price is INR ₹42.99. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹892.65.

How do dividend payouts of Sandu Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Sandu Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.